A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease

Description

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other sites around the United States who are part of the CCFA Clinical Alliance. The aim of this study is to determine the effect of medication use and disease activity on the outcome of pregnancy among women with IBD up to 18 years from birth.

Conditions

Inflammatory Bowel Disease

Study Overview

Study Details

Study overview

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other sites around the United States who are part of the CCFA Clinical Alliance. The aim of this study is to determine the effect of medication use and disease activity on the outcome of pregnancy among women with IBD up to 18 years from birth.

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease

Condition
Inflammatory Bowel Disease
Intervention / Treatment

-

Contacts and Locations

San Francisco

Please Contact Jessica Lim For Further Information Regarding Other Sites' Locations, San Francisco, California, United States, 94115

San Francisco

University of California San Francisco, San Francisco, California, United States, 94115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Female patients with confirmed IBD diagnoses who are pregnant and taking immunosuppressants and/or biologic therapy
  • * Pregnant female patients younger than 18 years of age
  • * Confirmed multiple gestation

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Uma Mahadevan, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2025-06